DelMar Pharmaceuticals Inc  

(Public, OTCMKTS:DMPI)   Watch this stock  
Find more results for Jeffrey Garner
-0.030 (-5.44%)
Jul 31 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.52 - 0.57
52 week 0.47 - 1.03
Open 0.52
Vol / Avg. 39,750.00/28,267.00
Mkt cap 19.36M
P/E     -
Div/yield     -
EPS -0.10
Shares 35.20M
Beta     -
Inst. own 0%
May 28, 2015
DelMar Pharmaceuticals Inc at SeeThruEquity LLC Microcap Investor Conference
May 18, 2015
Q3 2015 DelMar Pharmaceuticals Inc Earnings Release

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -175.42% -
Return on average equity -481.68% -
Employees 4 -
CDP Score - -


999 Broadway W Suite 720
+1-604-6295989 (Phone)

Website links


DelMar Pharmaceuticals, Inc. formerly Berry Only Inc., is developing new drug candidates targeting orphan cancer indications. The Company’s product development programs VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and solid tumors, including lung cancer. The Company has opened an Investigational New Drug (IND) with the United States Food & Drug Administration (FDA) to begin Phase II human clinical trials with VAL-083 in patients suffering from glioblastoma multiforme (GBM). Glioblastoma multiforme (GBM) is the common and malignant form of brain cancer.

Officers and directors

Jeffrey A. Bacha President, Chief Executive Officer, Director
Age: 47
Scott Praill Chief Financial Officer
Age: 49
Dennis M. Brown Ph.D. Chief Scientific Officer, Director
Age: 65
William J. Garner M.D. Director
Age: 48
Robert J. Toth Jr Director
Age: 51
John K. Bell Independent Director
Age: 67
Lynda Sarah Cranston Independent Director
Age: 67
Erich Mohr Ph.D. Independent Director
Age: 60